Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Expired

Notice of Special Interest (NOSI): Collaborative and Innovative Research to Advance Regulatory Science: Partnership of FDA Centers of Excellence in Regulatory Science and Innovation (CERSI) and NIH Clinical and Translational Science Award (CTSA) Programs

National Institutes of Health

The National Institutes of Health (NIH)’s National Center for Advancing Translational Sciences (NCATS) and the Food and Drug Administration (FDA)’s Office of the Chief Scientist (OCS) intend to collaborate and foster partnership between the NIH’s Clinical and Translational Science Award (CTSA) Program and the FDA’s Centers of Excellence in Regulatory Science and Innovation (CERSI) Program to advance regulatory science by leveraging the resources and expertise from both programs.

Regulatory science is the science of developing tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products, which include medical devices, drugs, biologics, combination products, veterinary medicine, food, cosmetics, dietary supplements, and tobacco products. In addition to the product areas that FDA regulates, FDA also aims to target cross-cutting areas that have the potential to transform how FDA-regulated products are developed, evaluated, and utilized, such as digital health, artificial intelligence, data science, alternative methods, One Health, patient-centered outcomes, and behavior change/ social science. The FDA hosts the CERSI Program to foster robust and innovative approaches to advance regulatory science. The goal for the CERSIs to advance regulatory science individually and synergistically, under the CERSI Program led by the OCS’ Office of Regulatory Science and Innovation (ORSI) , through collaborative interactions with FDA scientific experts and funding offices.

Translational Science is the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process. The NIH supports the CTSA Program to develop innovative solutions that will improve the efficiency, quality, and impact of the process for turning observations in the laboratory, clinic, and community into interventions that improve the health of individuals and the public. The CTSA Program is a national, collaborative consortium led by the NCATS’ Division of Clinical Innovation .

This Notice of Special Interest (NOSI) related to the CTSA Program Collaborative and Innovative Acceleration (CCIA) Award ( PAR-22-167 : UG3/UH3 Clinical Trial Optional) Initiative describes the NIH and FDA research priorities for regulatory science. The respective shared goals of regulatory science and translational science provide opportunities to tackle high-impact concepts across all stages of the translational science spectrum . The CCIA Notice of Funding Opportunity (NOFO) PAR-22-167 supports synergistic activities that accelerate the translational research process through collaboration and innovation. This NOFO invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs), and/or external stakeholders.

This NOSI applies to due dates on or after February 15, 2024 and subsequent receipt dates through October 17, 2024. (Feb 15, 2024; June 18, 2024; Oct 17, 2024)

For eligibility information of this NOSI, please see the NOFO PAR-22-167 .

NOT-TR-24-006

Specialties

Engineering and Physical Sciences

Medical - Translational

Medical

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity